Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - Λέμφωμα, mantle-cell - Αντινεοπλασματικοί παράγοντες - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

kite pharma eu b.v., the netherlands tufsteen 1, 2132 nt hoofddorp - autologous anti-cd19-transduced cd3+ cells - disp.inf (ΔΙΑΣΠΟΡΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 0.4 - 2 x 10 8 κύτταρα - autologous anti-cd19-transduced cd3+ cells 0,4ce - other antineoplastic agents

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

medichrom a.e. - ΚΑΨΟΥΛΕΣ ΒΡΑΔΕΙΑΣ ΑΠΟΔΕΣΜΕΥΣΗΣ - 20mg/cap